Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus

Blood

Volumn 106, Issue 13, 2005, Pages 4152-4158

  Male, Christoph ^b   Foulon, Denise ^b   Hoogendoorn, Hugh ^b   Vegh, Patricia ^b   Silverman, Earl ^b   David, Michèle ^b   Mitchell, Lesley ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY;

ARTICLE; CHILD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 28844463067     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2048     Document Type: Article

References (43)

1. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis. Lupus. 1997;6:467-473.
2. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986;41:8-15.
3. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 1994;84:2854-2867.
4. Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res. 1995;78:1-31.
5. Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods. 1991;143:223-229.
6. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120-1125.
7. Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;148:3885-3891.
8. Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost. 1996;75:717-720.
9. Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype antibeta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129:499-506.
10. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832.
11. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102:2717-2723.
12. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisloff F. The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb Res. 2001;104:275-282.
13. Reber G, Schousboe I, Tincani A, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement: a collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost. 2002;88:66-73.
14. Arvieux J, Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost. 1998;80:393-398.
15. Tsutsumi A, Ichikawa K, Matsuura E, Sawada KI, Koike T. Heterogeneous behavior of anti-beta2-glycoprotein I antibodies on various commercially available enzyme immunoassay plates coated with beta2-glycoprotein I. J Rheumatol. 2000;27:391-396.
16. Donohoe S, Mackie IJ, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol. 2001;113:544-549.
17. Ishii Y, Nagasawa K, Mayumi T, Niho Y. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis. 1990;49:387-390.
18. Out HJ, van Vliet M, de Groot PG, Derksen RH. Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992;51:353-357.
19. Berube C, Mitchell L, David M, et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematodes: a cross-sectional study. Pediatr Res. 1998;44:351-356.
20. Male C, Mitchell L, Julian J, et al. Resistance to activated protein C associated with thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. 2001;97:844-849.
21. Levy DM, Massicotte MP, Harvey E, Hebert D, Silverman ED. Thromboembolism in paediatric lupus patients. Lupus. 2003;12:741-746.
22. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-640.
24. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185-1190.
25. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. " Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol. 1995;154:954-960.
26. Martinuzzo ME, Forastiero RR, Carreras LO. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol. 1995;89:397-402.
27. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996;76:916-924.
28. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996;75:456-459.
29. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordick LC, Carreras LO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost. 1997;78:1008-1014.
30. Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol. 1998;25:1104-1108.
31. Erickson EN Jr, Najmey SS, Keil LB, El Kadi HS, DeBari VA. Reference calibrators for IgG antibodies to beta2-glycoprotein I: preparation, properties and availability to investigators. Clin Chem. 1996;42:1116-1117.
32. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991;66:520-524.
33. Ginsberg JS, Brill-Edwards P, Johnston M, et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood. 1992;80:975-980.
34. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to beta2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39:1466-1474.
35. Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus: prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol. 1999;28:344-351.
36. Munoz-Rodriguez FJ, Reverter JC, Font J, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica. 2000;85:632-637.
37. Nojima J, Kuratsune H, Suehisa E, et al. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol. 2001;114:647-654.
38. Lee SS, Cho ML, Joo YS, et al. Isotypes of antibeta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:520-524.
39. von Scheven E, Glidden DV, Elder ME. Antibeta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2002;47:414-420.
40. Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am. 2001;27:499-505, v.
41. Male C, Lechner K, Eichinger S, et al. Clinical significance of lupus anticoagulants in children. J Pediatr. 1999;134:199-205.
42. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Matsuura E, Ikeda Y. Clinical significance of phospholipid-dependent anti-beta 2-glycoprotein I (beta 2-GPI) antibodies in systemic lupus erythematosus. Lupus. 1995;4:472-476.
43. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147-1152.